LSI: Rapid Nexus Secures Two New Patents in Q2

Rapid Nexus Nanotech Wound Solutions, Inc. (hashtag#LSIEurope23 Innovator) received two additional patents in Q2, bringing their total number of patents to four U.S. issued patents and six international issued patents. To date, Rapid Nexus has already proven to prevent amputations with their products. The company has developed a first of its kind nanotechnology wound dressing, along with devices that accelerate healing, to rapidly close chronic non-healing wounds. The wound treatment system consists of a nanotechnology wound gel dressing formulation (Hemastyl Rx®) and Gen-Ray®, a therapeutic heating device equipped with LEDs that increase the local blood circulation in order to accelerate the body’s reaction to Hemastyl Rx®. More recently, their wound product has also been shown to be 99.99% effective against Candida Auris, an emerging multidrug-resistant yeast. Congratulations to the Rapid Nexus team hitting these new milestones! This September we’ll be welcoming Dr. Margaret Kalmeta who has been selected to present Rapid Nexus at LSI Europe ‘23 in Barcelona Spain See Feature Here